Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FIN56
- Development stage
- Preclinical
- Lead developer
- Columbia University
- Modality
- Small Molecules
- Administration
- In Vitro, Intravenous
01
Overview
FIN56 is a small molecule and a well-characterized, specific inducer of ferroptosis—a form of regulated, iron-dependent cell death. Its mechanism involves promoting the degradation of glutathione peroxidase 4 (GPX4), a key lipid repair enzyme, and activation of squalene synthase, leading to depletion of coenzyme Q10 and lethal accumulation of lipid hydroperoxides. In preclinical studies, FIN56 demonstrates anti-tumor effects in cancer models by inducing ferroptosis and synergizes with autophagy-related processes, supporting its use as a tool compound for cancer research and potentially for therapeutic development in ferroptosis-sensitive malignancies[1][2][3][4][6][7][8].
- Other names
- 1,3,8-trihydroxy-6-methylanthracen-9(10H)-one
02
Targets
GPX4 (Glutathione peroxidase 4)FDFT1 (Squalene synthase)
Beyond the preview
Go deeper on FIN56.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FIN56.